A study of the association of higher parathormone levels with health-related quality of life in hemodialysis patients

Clinical Nephrology

Volumn 77, Issue 3, 2012, Pages 196-203

  Malindreto, Pavlos ^a   Sarafidis, Pantelis ^a   Lazaridis, Anastasios ^a   Nikolaidis, Pavlos ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Hemodialysis; KDSF; Quality of life; Secondary hyperparathyroidism; SHPT

Indexed keywords

ALFACALCIDOL; CINACALCET; PARATHYROID HORMONE; PARICALCITOL; VITAMIN D RECEPTOR; BIOLOGICAL MARKER; PTH PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH STATUS; HEMODIALYSIS; HUMAN; LONG TERM CARE; MALE; PAIN; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SECONDARY HYPERPARATHYROIDISM; AGED; BLOOD; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; GREECE; KIDNEY DISEASE; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL ASPECT; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; UPREGULATION;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; GREECE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; MALE; MIDDLE AGED; PAIN; PARATHYROID HORMONE; QUALITY OF LIFE; QUESTIONNAIRES; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84859510761     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107030     Document Type: Article

References (31)

1. Constitution of the World Health Organization. In: World Health Organization Handbook of basic documents. 5th ed. Geneva: Palais des Nations; 1952. p. 3-20.
2. Caskey FJ, Wordsworth S, Ben T, de Charro FT, Delcroix C, Dobronravov V, van Hamersvelt H, Henderson I, Kokolina E, Khan IH, Ludbrook A, Luman M, Prescott GJ, Tsakiris D, Barbullushi M, MacLeod AM; EURODICE group. Early referral and planned initiation of dialysis: what impact on quality of life? Nephrol Dial Transplant. 2003; 18: 1330-1338. doi:10.1093/ndt/gfg156 PubMed
3. Fukuhara S, Lopes AA, Bragg-Gresham JL, Kurokawa K, Mapes DL, Akizawa T, Bommer J, Canaud BJ, Port FK, Held PJ, The F, Dopps W; Worldwide Dialysis Outcomes and Practice Patterns Study. Health-related quality of life among dialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2003; 64: 1903-1910.
4. Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE Jr. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol. 1996; 7: 763-773. PubMed
5. Mapes DL, Lopes AA, Satayathum S, McCullough KP, Goodkin DA, Locatelli F, Fukuhara S, Young EW, Kurokawa K, Saito A, Bommer J, Wolfe RA, Held PJ, Port FK. Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int. 2003; 64: 339-349.
6. Mingardi G. From the development to the clinical application of a questionnaire on the quality of life in dialysis. The experience of the Italian Collaborative DIA-QOL (Dialysis Quality of Life) Group. Nephrol Dial Transplant. 1998; 13 (Suppl 1): 70-75.
7. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol. 2001; 12: 2797-2806. PubMed
8. Mingardi G, Cornalba L, Cortinovis E, Ruggiata R, Mosconi P, Apolone G; DIA-QOL Group. Health-related quality of life in dialysis patients. A report from an Italian study using the SF-36 Health Survey. Nephrol Dial Transplant. 1999; 14: 1503-1510. doi:10.1093/ndt/14.6.1503 PubMed
9. Malindretos P, Sarafidis P, Spaia S, Sioulis A, Zeggos N, Raptis V, Kitos V, Koronis C, Kabouris C, Zili S, Grekas D. Adaptation and validation of the Kidney Disease Quality of Life-Short Form questionnaire in the Greek language. Am J Nephrol. 2010; 31: 9-14.
10. Locatelli F, Covic A, Eckardt KU, Wiecek A, Vanholder R; ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2009; 24: 348-354.
11. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005; 16: 2180-2189.
12. Unruh M, Benz R, Greene T, Yan G, Beddhu S, De-Vita M, Dwyer JT, Kimmel PL, Kusek JW, Martin A, Rehm-McGillicuddy J, Teehan BP, Meyer KB; HEMO Study Group. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int. 2004; 66: 355-366.
13. Coen G, Ballanti P, Bonucci E, Calabria S, Costantini S, Ferrannini M, Giustini M, Giordano R, Nicolai G, Manni M, Sardella D, Taggi F. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron. 2002; 91: 103-111.
14. Gallieni M, Cucciniello E, D'Amaro E, Fatuzzo P, Gaggiotti A, Maringhini S, Rotolo U, Brancaccio D; Collaborating nephrologists of the CARDIALISI Study Group. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study. J Nephrol. 2002; 15: 165-170.
15. Owda A, Elhwairis H, Narra S, Towery H, Osama S. Secondary hyperparathyroidism in chronic hemodialysis patients: prevalence and race. Ren Fail. 2003; 25: 595-602.
16. Salem MM. Hyperparathyroidism in the hemodialysis population: a survey of 612 patients. Am J Kidney Dis. 1997; 29: 862-865.
17. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int. 2008; 73: 1296-1302.
18. Shinaberger CS, Kopple JD, Kovesdy CP, McAllister CJ, van Wyck D, Greenland S, Kalantar-Zadeh K. Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2008; 3: 1769-1776.
19. Schumock GT, Andress D, E Marx S, Sterz R, Joyce AT, Kalantar-Zadeh K. Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in predialysis CKD patients. Curr Med Res Opin. 2008; 24: 3037-3048.
20. Schumock GT, Andress DL, Marx SE, Sterz R, Joyce AT, Kalantar-Zadeh K. Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients. Nephron Clin Pract. 2009; 113: c54-c61. doi:10.1159/000228076 PubMed
21. Cozzolino M, Brandenburg V. Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U". Clin Nephrol. 2009; 71: 593-601.
22. Evans RW, Manninen DL, Garrison LP Jr, Hart LG, Blagg CR, Gutman RA, Hull AR, Lowrie EG. The quality of life of patients with end-stage renal disease. N Engl J Med. 1985; 312: 553-559. doi:10.1056/NEJM198502283120905 PubMed
23. Athienites NV, Miskulin DC, Fernandez G, Bunnapradist S, Simon G, Landa M, Schmid CH, Greenfield S, Levey AS, Meyer KB. Comorbidity assessment in hemodialysis and peritoneal dialysis using the index of coexistent disease. Semin Dial. 2000; 13: 320-326.
24. Levey AS, Athienites NV and Gassman JJ. Comorbodity assessment in the HEMO study: an interim report (abstract). J Am Soc Nephrol, 1997.
25. Green J, Fukuhara S, Shinzato T, Miura Y, Wada S, Hays RD, Tabata R, Otsuka H, Takai I, Maeda K, Kurokawa K. Translation, cultural adaptation, and initial reliability and multitrait testing of the Kidney Disease Quality of Life instrument for use in Japan. Qual Life Res. 2001; 10: 93-100.
26. Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res. 1994; 3: 329-338.
27. Laupacis A, Muirhead N, Keown P, Wong C. A disease-specific questionnaire for assessing quality of life in patients on hemodialysis. Nephron. 1992; 60: 302-306.
28. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30: 473-483.
29. Grinstead C, Snell L. Discrete probability distributions. In: Doyle P (ed). Introduction to Probality. 2nd ed. American Mathematical Society; 2006. p. 1-40.
30. Mingardi G. Quality of life and end stage renal disease therapeutic programs. DIA-QOL Group. Dialysis quality of life. Int J Artif Organs. 1998; 21: 741-747.
31. Johansen KL, Chertow GM. Chronic kidney disease mineral bone disorder and health-related quality of life among incident end-stage renaldisease patients. J Ren Nutr. 2007; 17: 305-313.